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77% of total costs, with an average cost of R$ 67,319 per transplant. ConClusions: 
Organ transplant accounts for the majority of hospital health care costs in cirrhosis 
patients in the Brazilian public health care system. Considering patients with HCV 
treatment and cirrhosis, the average cost per patient was around 78% higher than 
the general cirrhosis patient.
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objeCtives: To assess the burden of hospitalizations related to Chronic Hepatitis 
C (CHC) in France in 2012 and to benchmark it to the 2009 estimate. Methods: All 
hospital stays with chronic viral hepatitis C (ICD-10 code B18.2) as principal, related 
or significantly associated diagnosis were extracted from the PMSI 2012 (French 
Medical Information System Program) database. Through an algorithm and a medi-
cal review, hospitalizations not related to CHC were excluded. Patients were assigned 
to a liver disease stage: F0-F3; compensated cirrhosis; decompensated cirrhosis; 
hepatocellular carcinoma; liver transplant. Same database and method (without 
making the distinction between compensated/decompensated cirrhosis) were used 
in 2009 allowing descriptive benchmark. Valuation was performed on French official 
tariffs for 2009 and 2012 and expressed in 2013 value (Euros). Results: 22,056 hos-
pitalizations were extracted in 2012 vs 27,258 in 2009 corresponding to 12,040 and 
15,482 patients, respectively. Sex-ratio M/F increased between 2009 and 2012 (1.66 
vs 1.78), as well as proportion of patients aged of 50 years old and over (60% vs 70%). 
In 2012, 5,834 patients were in F0-F3 fibrosis stage, 3,547 had cirrhosis and 2,105 
had hepatocellular carcinoma. Crude estimates for the evolution for these stages 
between 2009 and 2012 was -32%, -36% and +17%, respectively. Between 2009 and 
2012, number of liver biopsies was reduced by one third, and also less liver trans-
plants were performed (293 vs 254). Overall, the economic burden of hospitalizations 
related to CHC was € 60 millions in 2012, 8% lower than in 2009. ConClusions: 
3 major facts were highlighted: the decline in the number of liver biopsies, the 
decrease in the number of patients hospitalized for cirrhosis and the increase in 
patients hospitalized for hepatocellular carcinoma. This increase might be due to 
an improvement in screening techniques and aging of the population.
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objeCtives: To assess the mean annual cost of patients hospitalized for Chronic 
Hepatitis C (CHC) in France stratified by liver disease stage. Methods: Patients 
hospitalized for chronic viral hepatitis C (ICD-10 code B18.2) were identified in 
the PMSI-MCO 2010-2012 database (French Medical Information System Program- 
Medicine, Surgery, Obstetric) between January, 1st 2010 and December, 31st 2012 and 
tracked in the PMSI-SSR/HAD databases (post-acute care/hospitalizations at home: 
alternative management of care). An algorithm and a medical review excluded 
people under 18 years old, viral co-infected patients and non CHC related stays. 
During the study period, patients were followed from their first stay to censoring 
(i. e December 31st 2012 or death). For each patient, cumulative time in days in the 
different liver disease stages (F0-F3 fibrosis; compensated cirrhosis; decompensated 
cirrhosis; hepatocellular carcinoma; liver transplant) were calculated. Associated 
costs during these periods were added up and a mean annual cost per patient per 
liver disease stage estimated. As only inpatient deaths are captured into the PMSI, 
estimated outpatient deaths were imputed. Valuation was performed considering 
the national costs study (ENCC) expressed in 2013 Euro. Results: 58,405 stays 
were identified, extracted and considered as directly related to CHC corresponding 
to 26,621 patients. 743 additional hospitalizations were extracted from PMSI SSR/
HAD. Patients were 56±13.5 years old on average, 62% were male. Mean annual costs 
of patients hospitalized for CHC reason were: € 1,107 for F0-F3 fibrosis; € 2,104 for 
compensated cirrhosis; € 10,400 for decompensated cirrhosis; € 11,739 for hepatocel-
lular carcinoma; € 62,098 for 1st year of liver transplant and € 7,449 for subsequent 
year. ConClusions: CHC patients are mainly managed in acute care. Costs associ-
ated to CHC complications are important. These estimated hospital-related costs 
will be useful to populate cost-effectiveness and disease cost models.
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objeCtives: Opioid-induced constipation (OIC) is the most common and distress-
ing side effect of opioid treatment in patients with chronic pain. There are limited 
data to estimate the occurrence of OIC; however, estimates in non-cancer patients 
range from 40-50% and can be as high as 90% in cancer patients. Increased resource 
utilisation is associated with the diagnosis and management of OIC; however, the 
economic burden of OIC remains under-reported. Methods: This review con-
sidered the cost of illness associated with OIC. A targeted literature review was 
conducted for all publications since 2000 that evaluated the economic burden of 
OIC. Databases used for the literature search were PubMed, Embase, and HEED. 
All costs were converted to a 2014 USD cost base. Results: Eleven studies were 
identified which reported direct health care costs associated with OIC. All stud-
ies reported increased direct costs related to OIC; however, estimates per coun-
try varied significantly. Direct health care costs specifically related to OIC ranged 
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objeCtives: Biosimilar infliximab (CT-P13) is the first licensed biosimilar in EU for 
Crohn’s disease (CD). It is expected that spread of biosimilars in the treatment of 
CD will lead to cost savings and it might improve access to biological therapies. The 
main aim of this study was to analyse the budget impact of introducing biosimilar 
infliximab for the treatment of CD in six Central Eastern European (CEE) coun-
tries’ – Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovakia – health 
care systems. Methods: This budget impact model estimates potential impact of 
biosimilar infliximab on health care budget over three-year time frame from third-
party payer perspective. Spreadsheet-based country specific population model was 
developed functioning in quarter year time units. The model tracked movement of 
CD population between main states: 1) immune therapy, 2) infliximab, 3) biosimilar 
infliximab, 4) adalimumab. Switching between biologics and biosimilar infliximab 
was taken into consideration as well. In scenario analyses different rates of inter-
changing and switching were analysed. A -25% price difference was assumed for 
biosimilar infliximab compared to originator. Budget impact was calculated as dif-
ference in total cost of scenarios with and without biosimilar infliximab. Results: 
In 2013,4, 625 CD patients were treated with biologicals in the CEE. Over the 3-year 
period with gradually interchanging 80% of infliximab to biosimilar infliximab is 
expected to lead to a net benefit of 16,635,000 euros compared to the scenario in 
which biosimilar infliximab would not be available. In scenario in which inter-
changeabilty was disallowed the budget savings amounted to 7,842,000 euros. If 
budget savings were spent on reimbursement of additional biosimilar infliximab 
treatments, approximately further 889 or 420 patients could be treated in the six 
countries, respectively. ConClusions: Introduction of biosimilar infliximab treat-
ment for CD in CEE is predicted to bring substantial cost savings or increase of the 
number of patients with access to biological therapy.
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objeCtives: Originator products dominate the market, and as soon as patents 
expire prescribing patterns change as branded generics become the most often 
prescribed due to mandatory generic substitution in South Africa. This study inves-
tigated the prescribing patterns of proton pump inhibitors (PPIs). Methods: A 
retrospective, cross-sectional drug utilisation study was conducted on prescription 
data of a medical insurance scheme administrator in South Africa for 2011. The 
database contained 2 298 312 records for medicine, medical devices and proce-
dures. Results: A total of 22 198 PPIs were prescribed to 7 504 patients (average age: 
45.09 (SD= 15.82) years) at a cost of R3 931 241.43. The average cost per PPI prescrip-
tion was R177.10 (SD= R140.62). The average cost for a generic PPI prescription was 
R147.01 compared to R276.17 for a prescription for an originator product. Five differ-
ent PPIs were prescribed. Omeprazole, lansoprazole and pantoprazole had branded 
generics available on the market, whereas esomeprazole and rabeprazole only had 
originator products on the market. Omeprazole was the most frequently prescribed 
(47.05% of all PPI prescriptions). Nearly all (98.90%) omeprazole prescriptions were 
for one of its eight branded generics. Esomeprazole had the highest average cost 
per prescription of R289.23. The 40mg tablet formulation of esomeprazole was the 
most commonly prescribed. Less than 2% of PPI prescriptions were for rabeprazole. 
Most prescriptions were for Schedule 4 products (prescription-only), with only 3.91% 
Schedule 2 prescriptions (over-the-counter, prescribed in lower dosages for acute 
symptoms over a short period of time). Overall in this study, 76.70% of PPI prescrip-
tions were for branded generics. ConClusions: Omeprazole dominated PPI pre-
scribing, whilst esomeprazole was the most expensive PPI. It will be important to 
further investigate the impact of patent expiry and the introduction of new branded 
generics on PPI prescribing patterns. The study confirmed the significant price dif-
ferences for PPIs between branded generics and originator products.
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objeCtives: Estimate direct health care costs associated with cirrhosis from a bra-
zilian public payer perspective (SUS). Methods: A retrospective study of a public 
claims database (DATASUS) was used to assess direct health care costs associated 
with cirrhosis between 2008 and 2012. Patients with cirrhosis were identified based 
on ICD-10 codes (K70.3, K71.7, K74.3-K74.6). The retrospective analysis considered 
inpatient costs and outpatient treatment costs of patients during the 4 year time 
frame. Medication costs were defined as a weighted average during the period of 
analysis considering official government price lists available at www. compras-
net. gov. br. A sub analysis was carried out for cirrhotic patients with hepatitis C 
(HCV) treatment, defined as patients treated with peg-interferon with ribavirin 
(PR). Results: Between 2008-2012, 120,082 patients were hospitalized due to cir-
rhosis (49% of patients accounted by ICD K746) with a total treatment cost of R$ 404 
million, 68% accounting for transplant (R$ 276 million), 30% for outpatient proce-
dures (R$ 121 million), 2% for surgical procedures (R$ 6 million) and the remainder 
for exams and diagnostics. Patients were hospitalized for an average of 10,1 days 
per year, with an average cost of R$ 2,806 (R$2.149- R$ 3,757) per hospitalization 
event and R$ 3.378 (R$ 2.523-4.579) per patient. The average cost for transplant was 
R$ 52.912 (R$43.304-70.274). Between 2008 and 2012 2.933 patients were hospital-
ized for cirrhosis having received HCV treatment with a total cost of R$ 19 million. 
The average inpatient cost for HCV-cirrhosis patients was R$ 4,999 for 11,2 days of 
hospitalization. Organ transplants-associated costs accounted for R$ 15 million, 
